PHLDA2

Across TCGA pan-cancer cohorts, PHLDA2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PHLDA2 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PHLDA2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PHLDA2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where PHLDA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.124	1.000	.038	9	view →
PDAC	DFS	Median	II,III,IV	0.609	0.225	.003	7	view →
GBM	DFS	Median	All	0.473	0.819	.012	7	view →
LSCC	OS	Median	All	0.839	0.948	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PHLDA2–CCRCC (DFS)

Open the CCRCC breakdown →